Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP186201.RA6d6C59dWXzxfK3X6_ntkpVy3SszzAHlQXHrjlqAAKHQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP186201.RA6d6C59dWXzxfK3X6_ntkpVy3SszzAHlQXHrjlqAAKHQ130_assertion type Assertion NP186201.RA6d6C59dWXzxfK3X6_ntkpVy3SszzAHlQXHrjlqAAKHQ130_head.
- NP186201.RA6d6C59dWXzxfK3X6_ntkpVy3SszzAHlQXHrjlqAAKHQ130_assertion description "[Because HER-2 extracellular domain (ECD) levels have been correlated with disease progression in the metastatic setting, we considered trastuzumab salvage therapy plus a taxane in heavily pretreated trastuzumab-naive relapsed breast cancer patients with high serum levels of HER-2 ECD (> or =15 ng/ml).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP186201.RA6d6C59dWXzxfK3X6_ntkpVy3SszzAHlQXHrjlqAAKHQ130_provenance.
- NP186201.RA6d6C59dWXzxfK3X6_ntkpVy3SszzAHlQXHrjlqAAKHQ130_assertion evidence source_evidence_literature NP186201.RA6d6C59dWXzxfK3X6_ntkpVy3SszzAHlQXHrjlqAAKHQ130_provenance.
- NP186201.RA6d6C59dWXzxfK3X6_ntkpVy3SszzAHlQXHrjlqAAKHQ130_assertion SIO_000772 18448549 NP186201.RA6d6C59dWXzxfK3X6_ntkpVy3SszzAHlQXHrjlqAAKHQ130_provenance.
- NP186201.RA6d6C59dWXzxfK3X6_ntkpVy3SszzAHlQXHrjlqAAKHQ130_assertion wasDerivedFrom befree-20140225 NP186201.RA6d6C59dWXzxfK3X6_ntkpVy3SszzAHlQXHrjlqAAKHQ130_provenance.
- NP186201.RA6d6C59dWXzxfK3X6_ntkpVy3SszzAHlQXHrjlqAAKHQ130_assertion wasGeneratedBy ECO_0000203 NP186201.RA6d6C59dWXzxfK3X6_ntkpVy3SszzAHlQXHrjlqAAKHQ130_provenance.